INNOVENT BIOLGCS UNSP/ADR - IVBIY STOCK NEWS

Welcome to our dedicated page for INNOVENT BIOLGCS UNSP/ADR news (Ticker: IVBIY), a resource for investors and traders seeking the latest updates and insights on INNOVENT BIOLGCS UNSP/ADR stock.

Innovent Biologics, Inc. (IVBIY) is a renowned biopharmaceutical company specializing in the development, manufacturing, and commercialization of high-quality medicines for various diseases, including oncology, cardiovascular, metabolic, autoimmune, and ophthalmology. The company's recent achievements include the publication of results from the Phase 2 TRUST-I study evaluating taletrectinib, a next-generation ROS1 tyrosine kinase inhibitor, and the development of innovative therapies targeting CLDN18.2/CD3 and PD-1/IL-2 pathways.

Innovent Biologics has established itself as a leader in the biopharmaceutical industry, with a strong focus on empowering patients worldwide with affordable, effective treatments. With a diverse portfolio of products and ongoing clinical trials, the company continues to drive innovation and advance the field of biopharmaceuticals.

07/02/2023 08:00 PM

News

Innovent and IASO Bio Announce the NMPA Approval of FUCASO®, the First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed or Refractory Multiple Myeloma

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

06/25/2023 08:00 PM

News

Innovent and RemeGen Enter into Clinical Trial Collaboration Investigating Combination Therapy of TYVYT® (sintilimab injection) and Novel ADC Candidates for Advanced Solid Tumors in China

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

06/05/2023 08:00 PM

News

Innovent Presents Phase 1 Clinical Data of IBI351 (KRASG12C Inhibitor) as Monotherapy for Metastatic Colorectal Cancer at the 2023 ASCO Annual Meeting

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

06/05/2023 08:00 PM

News

Innovent and IASO Bio Updated Efficacy and Safety Clinical Data of Equecabtagene Autoleucel (BCMA CAR-T Cell Therapy) for Multiple Myeloma at the 2023 ASCO Annual Meeting

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

06/04/2023 08:00 PM

News

Innovent Presents Phase 1b Clinical Data of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2023 ASCO Annual Meeting

Rhea-AI Summary

Innovent Biologics, Inc. announced Phase 1b clinical data of IBI110 in the first-line treatment of gastric cancer and hepatocellular carcinoma. In the gastric cancer study, 15 patients achieved a partial response, with an overall response rate of 88.2%. The median duration of response was 10.6 months, and the median progression-free survival was 12.9 months. In the hepatocellular carcinoma study, the objective response rate was 29.6%, and the disease control rate was 85.2%. The median progression-free survival was 9.9 months. Both studies showed manageable safety profiles.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

06/03/2023 08:00 PM

News

Innovent Updates Phase 1b Data of IBI939 (Anti-TIGIT Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-selected NSCLC at the 2023 ASCO Annual Meeting

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

06/02/2023 07:59 PM

News

Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

06/01/2023 08:00 PM

News

Innovent Enters into Clinical Trial Collaboration with Merck KGaA, Darmstadt, Germany Investigating Combination Therapy of IBI351 (KRASG12C Inhibitor) and Cetuximab (ERBITUX®)for KRASG12C-mutated NSCLC in China

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

05/16/2023 08:00 PM

News

Innovent Announces Clinical Data of Multiple Trials Will be Presented at the 2023 ASCO and EHA Annual Meetings

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

05/14/2023 08:00 PM

News

Innovent Receives NMPA Breakthrough Designation for IBI351 (KRASG12C Inhibitor) as Monotherapy for Previously Treated Advanced Colorectal Carcinoma

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

FAQ

What is the current stock price of INNOVENT BIOLGCS UNSP/ADR (IVBIY)?

The current stock price of INNOVENT BIOLGCS UNSP/ADR (IVBIY) is $19.15 as of November 21, 2024.

What is the market cap of INNOVENT BIOLGCS UNSP/ADR (IVBIY)?

The market cap of INNOVENT BIOLGCS UNSP/ADR (IVBIY) is approximately 7.9B.

What is Innovent Biologics, Inc. known for?

Innovent Biologics, Inc. is renowned for its development, manufacturing, and commercialization of high-quality medicines for various diseases, including oncology, cardiovascular, metabolic, autoimmune, and ophthalmology.

What are some recent achievements of Innovent Biologics?

Recent achievements of Innovent Biologics include the publication of results from the Phase 2 TRUST-I study evaluating taletrectinib and the development of innovative therapies targeting CLDN18.2/CD3 and PD-1/IL-2 pathways.

How does Innovent Biologics empower patients worldwide?

Innovent Biologics aims to provide affordable, high-quality biopharmaceuticals to patients worldwide, ensuring access to effective treatments for various diseases.